retatrutide glp-1 gip glucagon agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide: The triple agonist powering

Upon binding to their respective receptors on pancreatic beta cells, GIP and GLP-1 enhance insulin secretion in a glucose-dependent manner

[DOI] [PMC free article] [PubMed] [Google Scholar] 111.Benetti E., Mastrocola R., Vitarelli G., Cutrin J.C., Nigro D., Chiazza F., Mayoux E., Collino M., Fantozzi R

One that political scientists Donald Stokes called Pasteur's Quadrant

Exploration of Drug Science

27 In the pancreas, GLP-1 receptor (GLP-1R) activation in islet cells promotes glucose-dependent insulin secretion from -cells, 28 inhibits glucagon release from -cells, and suppresses exocrine function via induction of pancreatic somatostatin

Additionally, there was GLP1 RA expression in tumor cells and infiltrating immune cells in human TNBC specimens, suggesting potential immunomodulatory effects that can impact treatment response